Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 30, 2017	Dec. 31, 2016	Jan. 02, 2016
Cash Flows From Operating Activities
Net loss	$ (11,377,618)	$ (2,928,185)	$ (2,771,067)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of leasehold improvements and equipment	509,933	331,734	285,536
Amortization of intangibles	206,208	87,826	45,014
Share-based compensation expense	4,604,749	1,193,782	1,977,611
Allowance for doubtful trade receivables	(411,475)	713,122	329,844
Gain from disposal of assets	(5,467,268)	0	0
Loss from disposal of equipment	4,649	7,114	19,643
Loss from impairment of intangibles	0	0	19,495
Loss on debt extinguishment	0	313,099	0
Non-cash financing costs	120,759	110,161	188,442
Changes in operating assets and liabilities:
Trade receivables	937,093	(4,114,561)	(873,726)
Inventories	2,177,263	240,851	(4,439,458)
Prepaid expenses and other assets	(296,312)	(133,855)	(82,124)
Accounts payable	(2,363,653)	(245,670)	2,772,350
Accrued expenses	1,471,976	867,307	449,180
Customer deposits and other	(67,855)	117,008	37,567
Deferred rent	179,873	503,671	(69,445)
Due to officer	(32,500)	0	0
Net cash used in operating activities	(9,804,178)	(2,936,596)	(2,111,138)
Cash Flows From Investing Activities
Proceeds from disposal of assets, net of transaction costs	5,953,390	0	0
Purchases of leasehold improvements and equipment	(1,167,506)	(1,504,922)	(525,231)
Purchases of intangible assets	(183,958)	(220,000)	(122,500)
Net cash provided by (used in) investing activities	4,601,926	(1,724,922)	(647,731)
Cash Flows From Financing Activities
Proceeds from issuance of common stock, net of issuance costs	46,594,216	5,717,474	1,974,893
Proceeds from exercise of stock options	3,037,960	716,612	94,846
Proceeds from loan payable	0	0	2,500,000
Payment of debt issuance cost	(75,178)	(176,836)	(15,000)
Principal payments on loan payable	0	(5,000,000)	0
Cash paid for debt extinguisment costs	0	(281,092)	0
Principal payments on capital leases	(608,327)	(221,883)	(210,948)
Net cash provided by financing activities	48,948,671	754,275	4,343,791
Net increase (decrease) in cash	43,746,419	(3,907,243)	1,584,922
Cash Beginning of Year	1,642,429	5,549,672	3,964,750
Cash Ending of Year	45,388,848	1,642,429	5,549,672
Supplemental Disclosures of Cash Flow Information
Cash payments for interest	57,024	261,738	427,591
Supplemental Schedule of Noncash Investing Activity
Noncash consideration transferred for the acquisition of Healthspan Research LLC	1,187,430	0	0
Capital lease obligation incurred for purchases of equipment	514,899	156,655	303,933
Receivable from disposal of assets held at escrow	750,000	0	0
Inventory supplied to Healthspan Research, LLC for equity interest, at cost	0	20,318	0
Retirement of fully depreciated equipment - cost	57,424	90,803	121,213
Retirement of fully depreciated equipment - accumulated depreciation	$ (57,424)	$ (90,803)	$ (121,213)